Gene therapy and vaccine makers fall after FDA names Vinay Prasad as top vaccine official

Shares of vaccine maker Moderna MRNA.O and gene therapy developers fall between 12% and 22% after the U.S. FDA named Vinay Prasad as the director of its Center for Biologics Evaluation and Research (CBER)

Prasad was a fierce critic of COVID-19 vaccine and mask mandates

As the director of CBER, Prasad will oversee the regulation of vaccines and gene therapies

Shares of Moderna down 12.4%, Novavax NVAX.O down 5.2%, while Pfizer PFE.N, previously down after an announcement on medicine costs, extends losses to 3%

Shares of gene therapy developers such as Sarepta Therapeutics SRPT.O fall 21.5%, Taysha Gene Therapies TSHA.O fall 20.7%, Capricor Therapeutics CAPR.O down 20.3%

U.S.-listed shares of CRISPR Therapeutics CRSP.BN down 9.6%, Solid Biosciences SLDB.O down 15.3%,

MRNA down 41.3% and SRPT down 61.1% YTD